US EUA For Lilly’s Bamlanivimab Conditioned On Additional GMP Compliance Requirements

Letter of authorization for COVID-19 therapeutic made at troubled Lilly plant requires independent third-party oversight.

Coronavirus
fda balances quality against availability of covid-19 neutralizing antibody

The US Food and Drug Administration has found a way to authorize emergency use of an Eli Lilly and Company COVID-19 therapeutic even though the facility that manufactures the drug substance is in trouble with the agency over data integrity issues.

The Defense Department and the FDA’s parent agency, the Health and Human Service Department, agreed on 28 October to buy...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance